Eli Lilly & Co (LLY): Net Income
$20.64B
Year ended 2025-12-31
+49.0%
3-year compound annual growth
+27.2%
5-year compound annual growth
+24.0%
10-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.64B | +94.9% | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | $10.59B | +102.1% | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $5.24B | -16.1% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $6.24B | +11.9% | 2025-02-19, From 2022-01-01 |
| 2021-12-31 | $5.58B | -9.9% | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | $6.19B | -25.5% | 2023-02-22, From 2020-01-01 |
| 2019-12-31 | $8.32B | +157.4% | 2022-02-23, From 2019-01-01 |
| 2018-12-31 | $3.23B | n/m | 2021-02-17, From 2018-01-01 |
| 2017-12-31 | -$204.10M | n/m | 2020-02-19, From 2017-01-01 |
| 2016-12-31 | $2.74B | +13.7% | 2019-02-19, From 2016-01-01 |
| 2015-12-31 | $2.41B | +0.7% | 2018-02-20, From 2015-01-01 |
| 2014-12-31 | $2.39B | -49.0% | 2017-02-21, From 2014-01-01 |
| 2013-12-31 | $4.68B | +14.6% | 2016-02-19, From 2013-01-01 |
| 2012-12-31 | $4.09B | -6.0% | 2015-02-19, From 2012-01-01 |
| 2011-12-31 | $4.35B | -14.2% | 2014-02-19, From 2011-01-01 |
| 2010-12-31 | $5.07B | +17.1% | 2013-02-21, From 2010-01-01 |
| 2009-12-31 | $4.33B | n/m | 2012-02-24, From 2009-01-01 |
| 2008-12-31 | -$2.07B | n/m | 2011-02-22, From 2008-01-01 |
| 2007-12-31 | $2.95B | n/a | 2010-02-22, From 2007-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Eli Lilly & Co (LLY) | 2025-12-31 | $20.64B | +94.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $18.25B | +6.6% |
| Pfizer Inc (PFE) | 2025-12-31 | $7.77B | -3.2% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $4.23B | -1.2% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $7.05B | n/m |
| Johnson & Johnson (JNJ) | 2025-12-28 | $26.80B | +90.6% |
| Abbott Laboratories (ABT) | 2025-12-31 | $6.52B | -51.3% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.41B | n/m |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $4.50B | +2.1% |
Compare LLY, MRK, PFE, ABBV side by side · Screen every company in Pharmaceutical Preparations ↗